曲妥珠单抗德鲁替康(DS-8201a)用于晚期HER2阳性胃癌患者:剂量扩展1期研究
这项开放标签、剂量递增和剂量扩展1期研究在美国8家和日本6家医院开展,44例既往接受曲妥珠单抗的HER2阳性胃或胃食管交界癌患者接受曲妥珠单抗德鲁替康5.4 mg/kg或6.4 mg/kg每3周一次静脉给药。全部患者发生至少1例治疗中出现的不良事件,19例(43.2%;95%CI 28.3-59.0)获确认的客观缓解。曲妥珠单抗德鲁替康安全性可控,在经重度治疗患者中显示初步活性,支持进一步研究。
要点
- 44例HER2阳性胃或胃食管交界癌患者接受曲妥珠单抗德鲁替康推荐扩展剂量5.4 mg/kg或6.4 mg/kg每3周一次。
- 全部患者发生至少1例治疗中出现的不良事件,最常见≥3级为贫血13例(30%)。
- 19例(43.2%;95%CI 28.3-59.0)获确认的客观缓解。
核心结论
- 曲妥珠单抗德鲁替康安全性可控,在经重度治疗的HER2阳性胃或胃食管交界癌患者中显示初步活性,支持曲妥珠单抗治疗后进一步研究。
研究设计与样本
- 开放标签、剂量递增和剂量扩展1期研究,在美国8家和日本6家医院开展。
- 44例HER2阳性胃或胃食管交界癌患者接受曲妥珠单抗德鲁替康推荐扩展剂量5.4 mg/kg或6.4 mg/kg静脉给药,每3周一次,直至撤回同意、不可接受毒性或疾病进展。
- 主要终点为安全性和初步活性(研究者评估的客观缓解比例)。
主要发现
- 2015年8月28日至2018年8月10日,44例HER2阳性胃或胃食管交界癌患者接受至少1剂曲妥珠单抗德鲁替康推荐扩展剂量。
- 全部患者发生至少1例治疗中出现的不良事件;最常见≥3级治疗中出现的不良事件包括贫血13例(30%)、中性粒细胞减少9例(20%)、血小板减少8例(18%)和白细胞减少7例(16%)。
- 11例(25%)患者发生严重治疗中出现的不良事件;肺炎4例(3例2级和1例3级);无因治疗中出现的不良事件导致的药物相关死亡。
- 44例中19例(43.2%;95%CI 28.3-59.0)获确认的客观缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody-drug conjugate with a humanised anti-HER2 antibody, cleavable peptide-based linker, and topoisomerase I inhibitor payload. A phase 1, non-randomised, open-label, multiple-dose study was done to assess the safety, tolerability, and activity of trastuzumab deruxtecan in HER2-expressing advanced solid tumours. The dose escalation (part 1) has previously been reported and the recommended doses for expansion of 5·4 mg/kg or 6·4 mg/kg were established. In this Article, we report the safety and preliminary activity results from this phase 1 trial in all patients with HER2-positive gastric or gastro-oesophageal junction cancer who received trastuzumab deruxtecan at the recommended doses for expansion. METHODS: This was an open-label, dose-escalation and dose-expansion phase 1 trial done at eight hospitals and clinics in the USA and six in Japan. Eligible patients were at least 18 years old in the USA and at least 20 years old in Japan and had advanced solid tumours (regardless of HER2 expression in dose escalation or HER2 expression or mutation in dose expansion). The recommended doses for expansion of 5·4 mg/kg or 6·4 mg/kg trastuzumab deruxtecan were administered intravenously to patients once every 3 weeks until withdrawal of consent, unacceptable toxicity, or progressive disease. In this Article, all patients with HER2-positive gastric or gastro-oesophageal junction cancer with previous trastuzumab treatment who received trastuzumab deruxtecan were analysed together. The primary endpoints of the study were safety and preliminary activity (proportion of patients who achieved an objective response as assessed by the investigators). The activity evaluable set included all patients who received at least one dose of trastuzumab deruxtecan at the recommended doses for expansion, and for whom both baseline and post-treatment activity data were available. The safety analysis set included all patients who received at least one dose of trastuzumab deruxtecan at the recommended doses for expansion. Enrolment for patients with gastric or gastro-oesophageal junction cancer has completed. This trial is registered at ClinicalTrials.gov, number NCT02564900, and ClinicalTrials.jp, number JapicCTI-152978. FINDINGS: Between Aug 28, 2015, and Aug 10, 2018, 44 patients with HER2-positive gastric or gastro-oesophageal junction cancer received at least one dose of trastuzumab deruxtecan at the recommended doses for expansion. All patients had at least one treatment-emergent adverse event. The most frequent grade 3 or worse treatment-emergent adverse events included anaemia (13 [30%]) and decreases in neutrophil (nine [20%]), platelet (eight [18%]), and white blood cell (seven [16%]) counts. Serious treatment-emergent adverse events occurred in 11 (25%) patients. There were four pneumonitis cases (three grade 2 and one grade 3). There were no drug-related deaths due to treatment-emergent adverse events. 19 (43·2%; 95% CI 28·3-59·0) of 44 patients had a confirmed objective response. INTERPRETATION: Trastuzumab deruxtecan had a manageable safety profile and showed preliminary activity in heavily pretreated patients with HER2-positive gastric or gastro-oesophageal junction cancer. These results support further investigation of trastuzumab deruxtecan for HER2-positive gastric or gastro-oesophageal junction cancer post-trastuzumab. FUNDING: Daiichi Sankyo Co, Ltd.
引用
- Shitara K, Iwata H, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol. 2019. PMID: 31047804. doi:10.1016/S1470-2045(19)30088-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。